-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2020 to 2024.
- Aerovate Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $1.24M, a 61.8% decline year-over-year.
- Aerovate Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $11.3M, a 5% decline year-over-year.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $11.3M, a 5% decline from 2023.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.9M, a 117% increase from 2022.
- Aerovate Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5.48M, a 168% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)